Swedish Orphan Biovitrum (STO: SOBI) has announced the commercial launch of Elocta (efmoroctocog alfa) in Europe.
Elocta is a recombinant human factor VIII Fc fusion protein with an extended half-life.
It is the first hemophilia treatment in the European Union to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze